A phase i study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors

Clinical Cancer Research

Volumn 19, Issue 15, 2013, Pages 4262-4272

  Venugopal, Balaji ^a   Baird, Richard ^b   Kristeleit, Rebecca S ^c   Plummer, Ruth ^e   Cowan, Richard ^f   Stewart, Adam ^b   Fourneau, Nele ^g   Hellemans, Peter ^g   Elsayed, Yusri ^h   Mcclue, Steve ^h   Smit, Johan W ^g   Forslund, Ann ^g   Phelps, Charles ^h   Camm, John ^d   Evans, T R Jeffry ^a   De Bono, Johann S ^b   Banerji, Udai ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e FREEMAN HOSPITAL   (United Kingdom)

^f CHRISTIE HOSPITAL   (United Kingdom)

^g JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^h JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; KI 67 ANTIGEN; QUISINOSTAT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHRONIC LIVER FAILURE; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOSE LIMITING TOXICITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; FATIGUE; FEMALE; HAIR FOLLICLE; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HISTONE ACETYLATION; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERTENSION; LETHARGY; LIVER FUNCTION TEST; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; PARESTHESIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; PRIORITY JOURNAL; QT PROLONGATION; REENTRY TACHYCARDIA; SIDE EFFECT; SKIN; SOLID TUMOR; ST SEGMENT DEPRESSION; T WAVE INVERSION; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICOLOGICAL PARAMETERS; TREATMENT RESPONSE; TUMOR BIOPSY; VOMITING; WEIGHT REDUCTION; ADVERSE DRUG REACTION; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; MIDDLE AGED; MONONUCLEAR CELL; NEOPLASMS; ORAL DRUG ADMINISTRATION; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LEUKOCYTES, MONONUCLEAR; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; YOUNG ADULT;

EID: 84881237713     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0312     Document Type: Article

References (23)

1. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128: 683-92.
2. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009;280:168-76.
3. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84.
4. Venugopal B, Evans TR. Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr Med Chem 2011;18:1658-71.
5. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous Tcell lymphoma. Oncologist 2007;12:1247-52.
6. Grant C, Rahman F, Piekarz R, Peer C, Frye R, Robey RW, et al. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther 2010;10:997-1008.
7. Arts J, King P, Marien A, Floren W, Belien A, Janssen L, et al. JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res 2009;15:6841-51.
8. Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, King P, et al. The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models. Leukemia 2009;23:1894-903.
9. Bohets H, Van Uytsel K, De Meulder M, King P, Hickson I, Forslund A, et al. Comparative tissue distribution of the HDAC inhibitor JNJ-26481585. EJC Supplements 2010;8:189.
10. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, MA: Little, Brown & Co; 1994, p253-256.
11. Korn E, Midthune D, Chen T, Rubinstein L, Christian M, Simon R. A comparison of two phase I trial designs. Stat Med 1994;13:1799-806.
12. CTCAE. National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. [published Aug 09, 2006; cited Sept 17, 2010] Available from: http://ctep.cancer.gov/protocolDevelopment/ electronicapplications/docs/ ctcaev3.pdf
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
14. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
15. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8:718-28.
16. Steele NL, Plumb JA, Vidal L, Tjornelund J, Knoblauch P, Rasmussen A, et al.Aphase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patientswith advanced solid tumors. Clin Cancer Res 2008;14:804-10.
17. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-31.
18. Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer 2006;5:57-60.
19. Shah MH, Binkley P, Chan K, Xiao J, Arbogast D, Collamore M, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006;12: 3997-4003.
20. Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, et al. Phase 2 trial of romidepsin in patientswith peripheral T-cell lymphoma. Blood 2011;117:5827-34.
21. Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007;25:3362-71.
22. Stuhmer T, Arts J, Chatterjee M, Borawski J, Wolff A, King P, et al. Preclinical anti-myeloma activity of the novel HDAC inhibitor-JNJ-26481585. Br J Haematol 2010;149:529-36.
23. Child F, Romero PO, Alvarez R, Bagot M, Stadler R, Weichenthal M, et al. Phase 2 multicenter trial of oral Quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA cutaneous T cell lymphoma. [abstract]. In: Proceedings of the 54th ASH Annual Meeting and Exposition; 2012 Dec 8-11; Atlanta, GA. Washington, DC: ASH; 2012. Abstract nr 3676.